RU2739987C2 - Множественные олигонуклеотидные фрагменты на пептидном носителе - Google Patents

Множественные олигонуклеотидные фрагменты на пептидном носителе Download PDF

Info

Publication number
RU2739987C2
RU2739987C2 RU2016150629A RU2016150629A RU2739987C2 RU 2739987 C2 RU2739987 C2 RU 2739987C2 RU 2016150629 A RU2016150629 A RU 2016150629A RU 2016150629 A RU2016150629 A RU 2016150629A RU 2739987 C2 RU2739987 C2 RU 2739987C2
Authority
RU
Russia
Prior art keywords
pmo
rxrrbr
cpp
conjugate
aon
Prior art date
Application number
RU2016150629A
Other languages
English (en)
Russian (ru)
Other versions
RU2016150629A3 (enExample
RU2016150629A (ru
Inventor
Тимоти Э. УИДЕН
Кэрол А. НЕЛЬСОН
Брюс М. ВЕНВОРТ
Николас П. КЛЕЙТОН
Эндрю ЛЕДЖЕР
Original Assignee
Джензим Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джензим Корпорейшн filed Critical Джензим Корпорейшн
Publication of RU2016150629A publication Critical patent/RU2016150629A/ru
Publication of RU2016150629A3 publication Critical patent/RU2016150629A3/ru
Application granted granted Critical
Publication of RU2739987C2 publication Critical patent/RU2739987C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RU2016150629A 2014-05-23 2015-05-22 Множественные олигонуклеотидные фрагменты на пептидном носителе RU2739987C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462002296P 2014-05-23 2014-05-23
US62/002,296 2014-05-23
PCT/US2015/032142 WO2015179742A1 (en) 2014-05-23 2015-05-22 Multiple oligonucleotide moieties on peptide carrier

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2020142530A Division RU2020142530A (ru) 2014-05-23 2015-05-22 Множественные олигонуклеотидные фрагменты на пептидном носителе

Publications (3)

Publication Number Publication Date
RU2016150629A RU2016150629A (ru) 2018-06-25
RU2016150629A3 RU2016150629A3 (enExample) 2018-12-24
RU2739987C2 true RU2739987C2 (ru) 2020-12-30

Family

ID=53366294

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2016150629A RU2739987C2 (ru) 2014-05-23 2015-05-22 Множественные олигонуклеотидные фрагменты на пептидном носителе
RU2020142530A RU2020142530A (ru) 2014-05-23 2015-05-22 Множественные олигонуклеотидные фрагменты на пептидном носителе

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2020142530A RU2020142530A (ru) 2014-05-23 2015-05-22 Множественные олигонуклеотидные фрагменты на пептидном носителе

Country Status (15)

Country Link
US (2) US20170182171A1 (enExample)
EP (1) EP3151841B1 (enExample)
JP (2) JP6825914B2 (enExample)
KR (1) KR102487942B1 (enExample)
CN (1) CN106459975B (enExample)
AR (1) AR101542A1 (enExample)
AU (1) AU2015263963B2 (enExample)
BR (1) BR112016027236A2 (enExample)
CA (1) CA2949104C (enExample)
IL (1) IL249064B (enExample)
MX (1) MX381946B (enExample)
RU (2) RU2739987C2 (enExample)
SG (2) SG10202004611SA (enExample)
TW (1) TWI726844B (enExample)
WO (1) WO2015179742A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI726844B (zh) 2014-05-23 2021-05-11 美商健臻公司 胜肽載體上之多重寡核苷酸部分
US11512327B2 (en) 2017-08-03 2022-11-29 Voyager Therapeutics, Inc. Compositions and methods for delivery of AAV
WO2019060522A2 (en) * 2017-09-22 2019-03-28 The Regents Of The University Of Colorado, A Body Corporate OLIGONUCLEOTIDES THIOMORPHOLINO FOR THE TREATMENT OF MUSCLE DYSTROPHY
CN112105625B (zh) * 2018-03-07 2024-12-31 赛诺菲 核苷酸前体、核苷酸类似物以及含其的寡聚化合物
US10765760B2 (en) * 2018-05-29 2020-09-08 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
US20220372063A1 (en) * 2019-09-05 2022-11-24 Sanofi Oligonucleotides containing nucleotide analogs
WO2021211572A1 (en) * 2020-04-14 2021-10-21 Oregon State University Antisense therapeutics for the treatment of coronavirus
WO2023034515A2 (en) * 2021-09-03 2023-03-09 Sarepta Therapeutics, Inc. Delivery of anitsense oligomers by mirror image peptides

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006056A1 (en) * 1993-08-20 1995-03-02 University Of Medicine & Dentistry Of New Jersey Bridged polycationic polymer-oligonucleotide conjugates and methods for preparing same
RU2275936C2 (ru) * 1999-07-28 2006-05-10 Санофи-Авентис Дойчланд Гмбх Конъюгаты и способ их получения, а также их применение для транспорта молекул через биологические мембраны
WO2012177639A2 (en) * 2011-06-22 2012-12-27 Alnylam Pharmaceuticals, Inc. Bioprocessing and bioproduction using avian cell lines
WO2014052276A1 (en) * 2012-09-25 2014-04-03 Genzyme Corporation Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004235396B2 (en) 2003-04-29 2010-11-25 Sarepta Therapeutics, Inc. Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells
CA2691673A1 (en) 2007-06-29 2009-01-08 Avi Biopharma, Inc. Tissue specific peptide conjugates and methods
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
US20110130346A1 (en) 2008-05-30 2011-06-02 Isis Innovation Limited Peptide conjugates for delvery of biologically active compounds
WO2009147368A1 (en) 2008-06-04 2009-12-10 Medical Research Council Peptides
EP3133160B1 (en) 2008-10-24 2018-12-12 Sarepta Therapeutics, Inc. Exon skipping compositions for dmd
HK1200484A1 (zh) 2011-09-14 2015-08-07 Translate Bio Ma, Inc. 多聚寡核苷酸化合物
US10358643B2 (en) * 2014-01-30 2019-07-23 Hoffmann-La Roche, Inc. Poly oligomer compound with biocleavable conjugates
TWI726844B (zh) 2014-05-23 2021-05-11 美商健臻公司 胜肽載體上之多重寡核苷酸部分

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006056A1 (en) * 1993-08-20 1995-03-02 University Of Medicine & Dentistry Of New Jersey Bridged polycationic polymer-oligonucleotide conjugates and methods for preparing same
RU2275936C2 (ru) * 1999-07-28 2006-05-10 Санофи-Авентис Дойчланд Гмбх Конъюгаты и способ их получения, а также их применение для транспорта молекул через биологические мембраны
WO2012177639A2 (en) * 2011-06-22 2012-12-27 Alnylam Pharmaceuticals, Inc. Bioprocessing and bioproduction using avian cell lines
WO2014052276A1 (en) * 2012-09-25 2014-04-03 Genzyme Corporation Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Peter Jarver et al, Molecular Therapy - Nucleic Acids, 12.06.2012. *
Pierce T.L. et al, Mini reviews in medicinal chemistry, 2005, vol. 5, N 1, 41-55. *

Also Published As

Publication number Publication date
AU2015263963B2 (en) 2021-02-18
SG10202004611SA (en) 2020-06-29
JP2021063128A (ja) 2021-04-22
BR112016027236A2 (pt) 2017-10-17
MX381946B (es) 2025-03-13
CN106459975A (zh) 2017-02-22
JP6825914B2 (ja) 2021-02-03
US20170182171A1 (en) 2017-06-29
AR101542A1 (es) 2016-12-28
MX2016015156A (es) 2017-03-27
JP2017517253A (ja) 2017-06-29
IL249064A0 (en) 2017-01-31
US20190388547A1 (en) 2019-12-26
AU2015263963A1 (en) 2016-12-01
JP7269968B2 (ja) 2023-05-09
EP3151841B1 (en) 2022-10-19
RU2020142530A (ru) 2021-04-26
WO2015179742A1 (en) 2015-11-26
US11103587B2 (en) 2021-08-31
TW201617373A (zh) 2016-05-16
KR20170005118A (ko) 2017-01-11
CA2949104A1 (en) 2015-11-26
RU2016150629A3 (enExample) 2018-12-24
EP3151841A1 (en) 2017-04-12
RU2016150629A (ru) 2018-06-25
IL249064B (en) 2021-07-29
SG11201608880VA (en) 2016-11-29
TWI726844B (zh) 2021-05-11
KR102487942B1 (ko) 2023-01-11
CA2949104C (en) 2023-09-26
CN106459975B (zh) 2020-03-27

Similar Documents

Publication Publication Date Title
JP7269968B2 (ja) ペプチド担体上の多重オリゴヌクレオチド部分
Tung et al. Preparation and applications of peptide− oligonucleotide conjugates
CN103282503B (zh) 用于细胞内递送核酸的小分子缀合物
EP2751128B1 (en) Cell-penetrating peptides having a central hydrophobic domain
KR102443631B1 (ko) Scn9a 안티센스 올리고뉴클레오티드
JP4974890B2 (ja) ペプチドが結合された、イノシン置換アンチセンスオリゴマー化合物および方法
TW202346591A (zh) 連結有載體胜肽的核酸
US20240390508A1 (en) Human transferrin receptor binding peptide-drug conjugate
KR20250153726A (ko) 타겟 세포 내로 올리고뉴클레오티드를 전달하기 위한 펩타이드-지질의 결합체를 포함하는 나노입자 및 이를 포함하는 약학적 조성물
Albertshofer et al. Structure− activity relationship study on a simple cationic peptide motif for cellular delivery of antisense peptide nucleic acid
EP4237010A1 (en) Peptide-based delivery of agents
WO2003094974A1 (en) Complexes for the delivery of biologically-active material to cells
HK1236387A1 (en) Multiple oligonucleotide moieties on peptide carrier
HK1236387B (en) Multiple oligonucleotide moieties on peptide carrier
TWI565476B (zh) 基於肽之活體內ｓｉＲＮＡ傳遞系統
HK1194389B (en) Cell-penetrating peptides having a central hydrophobic domain